Last update March 9, 2021
We do not have alternatives for Tolvaptan.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Tolvaptan in other languages or writings:
Tolvaptan belongs to this group or family:
Main tradenames from several countries containing Tolvaptan in its composition:
|Oral Bioavail.||56 (42 - 80)||%|
|Protein Binding||98 - 99||%|
|Tmax||2 - 4||hours|
|T½||9 (8 - 12)||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Diuretic and selective vasopressin V2 receptor antagonist.
Prescribed for the treatment of hyponatremia caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Administered orally in one or two daily doses.
We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.
Due to its pharmacokinetic properties (large volume of distribution, moderately high molecular weight and high percentage of protein binding (Osuka 2019 y 2014), it would be very unlikely for significant quantities to pass into breast milk.
It has been used in children, infants and even neonates for treating nephrotic syndrome, polycystic kidney disease and after cardiac surgery (Delbet 2020, Schaefer 2019, Kerling 2019, Koksoy 2018, Alzarka 2018, Tejero 2018, Katayama 2017, Gilbert 2017).